Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI3WFG)

• Drug Name: AMG 334 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMI3WFG

Molecule-Related Drug Atlas

Drug(s) Targeting Calcitonin gene-related peptide receptor (CGRPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ubrogepant	DM749I3	Migraine	8A80	Approved	[3]
Fremanezumab	DMDZY54	Hyperprolactinaemia	5A60.1	Approved	[4]
Galcanezumab	DMIZ1E8	Hyperprolactinaemia	5A60.1	Approved	[4]
Erenumab	DMWMCN0	Hyperprolactinaemia	5A60.1	Approved	[4]
Rimegepant	DMHOAUG	Migraine	8A80	Approved	[5]
MK-3207	DM6OLGC	Migraine	8A80	Phase 2	[6]
Telcagepant	DMFT5D6	Cluster headache	8A81.0	Phase 2	[7]
Olcegepant	DMVW5KR	Migraine	8A80	Phase 2	[8]
BI-44370	DMZR9OU	Migraine	8A80	Phase 2	[9]
LBR-101	DM4YA0D	Migraine	8A80	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcitonin gene-related peptide receptor (CGRPR)	TTY6O0Q	CALRL_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT02174861) A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.. U.S. National Institutes of Health.
• [2] EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
• [7] CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
• [8] Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
• [9] BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
• [10] Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.